Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia

ClinicalTrials.gov ID: NCT02679573

Public ClinicalTrials.gov record NCT02679573. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate the Safety and Efficacy of Intravenous to Oral Delafloxacin in Adult Subjects With Community-Acquired Bacterial Pneumonia

Study identification

NCT ID
NCT02679573
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Enrollment
860 participants

Conditions and interventions

Interventions

  • Delafloxacin Drug
  • Moxifloxacin Drug
  • Linezolid Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 13, 2016
Primary completion
Jul 30, 2018
Completion
Aug 6, 2018
Last update posted
Feb 26, 2020

2016 – 2018

United States locations

U.S. sites
25
U.S. states
18
U.S. cities
24
Facility City State ZIP Site status
Melinta 306 Study Site Montgomery Alabama 36106
Melinta 306 Study Site Newark Delaware 19718
Melinta 306 Study Site Coral Gables Florida 33134
Melinta 306 Study Site DeBary Florida 32713
Melinta 306 Study Site DeLand Florida 32720
Melinta 306 Study Site Fort Myers Florida 33901
Melinta 306 Study Site Miami Florida 33126
Melinta 306 Study Site Miami Florida 33185
Melinta 306 Study Site Louisville Kentucky 40202
Melinta 306 Study Site Natchitoches Louisiana 71457-6215
Melinta 306 Study Site Baltimore Maryland 21201
Melinta 306 Study Site Boston Massachusetts 02115
Melinta 306 Study Site Burlington Massachusetts 01805
Melinta 306 Study Site Saint Paul Minnesota 55104
Melinta 306 Study Site St Louis Missouri 63110
Melinta 306 Study Site Butte Montana 59701
Melinta 306 Study Site Omaha Nebraska 68124
Melinta 306 Study Site Newark New Jersey 07102
Melinta 306 Study Site Buffalo New York 14215
Melinta 306 Study Site Charlotte North Carolina 28203
Melinta 306 Study Site Cleveland Ohio 44106-5029
Melinta 306 Study Site Dayton Ohio 45402
Melinta 306 Study Site Rapid City South Dakota 57702
Melinta 306 Study Site Franklin Tennessee 37067
Melinta 306 Study Site Corsicana Texas 75110

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 65 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02679573, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 26, 2020 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02679573 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →